Hyperion Partners’s Pfizer PFE Stock Holding History

Hyperion Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,115	Closed	-$209K	–	68
2023 Q1	$209K	Buy	5,115 +13	+0.3%	+$561	0.19%	62
2022 Q4	$261K	Buy	+5,102	New	+$245K	0.25%	48

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hyperion Partners's PFE Position: Q2 2023 in Review

Hyperion Partners sold out of Pfizer (PFE) in Q2 2023, closing a stake of 5,115 shares — an estimated $209K sold.

Hyperion Partners first reported a position in PFE in Q4 2022 and held it in 2 quarters. The position peaked at $261K in Q4 2022. 3,044 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Hyperion Partners reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Hyperion Partners sold 5,115 Pfizer shares in Q2 2023, an estimated $209K.
Hyperion Partners first reported a position in Pfizer in Q4 2022 and held it in 2 quarters.
Hyperion Partners's Pfizer position peaked at $261K in Q4 2022.
3,044 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Hyperion Partners's 13F filing for Q2 2023, filed 11 Jul 2023.